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ABSTRACT
Hepatitis C virus (HCV) NS3 is a multifunctional protein composed of a protease domain and a helicase domain linked by a flex-
ible linker. Protease activity is required to generate viral nonstructural (NS) proteins involved in RNA replication. Helicase activ-
ity is required for RNA replication, and genetic evidence implicates the helicase domain in virus assembly. Binding of protease
inhibitors (PIs) to the protease active site blocks NS3-dependent polyprotein processing but might impact other steps of the vi-
rus life cycle. Kinetic analyses of antiviral suppression of cell culture-infectious genotype 1a strain H77S.3 were performed using
assays that measure different readouts of the viral life cycle. In addition to the active-site PI telaprevir, we examined an allosteric
protease-helicase inhibitor (APHI) that binds a site in the interdomain interface. By measuring nucleotide incorporation into
HCV genomes, we found that telaprevir inhibits RNA synthesis as early as 12 h at high but clinically relevant concentrations.
Immunoblot analyses showed that NS5B abundance was not reduced until after 12 h, suggesting that telaprevir exerts a direct
effect on RNA synthesis. In contrast, the APHI could partially inhibit RNA synthesis, suggesting that the allosteric site is not al-
ways available during RNA synthesis. The APHI and active-site PI were both able to block virus assembly soon (<12 h) after
drug treatment, suggesting that they rapidly engage with and block a pool of NS3 involved in assembly. In conclusion, PIs and
APHIs can block NS3 functions in RNA synthesis and virus assembly, in addition to inhibiting polyprotein processing.
IMPORTANCE
The NS3/4A protease of hepatitis C virus (HCV) is an important antiviral target. Currently, three PIs have been approved for
therapy of chronic hepatitis C, and several others are in development. NS3-dependent cleavage of the HCV polyprotein is re-
quired to generate the mature nonstructural proteins that form the viral replicase. Inhibition of protease activity can block RNA
replication by preventing expression of mature replicase components. Like many viral proteins, NS3 is multifunctional, but how
PIs affect stages of the HCV life cycle beyond polyprotein processing has not been well studied. Using cell-based assays, we show
here that PIs can directly inhibit viral RNA synthesis and also block a late stage in virus assembly/maturation at clinically rele-
vant concentrations.
Chronic infection with the hepatitis C virus (HCV) is a leadingcause of end-stage liver disease and hepatocellular carcinoma.
HCV is an RNA virus with a cytoplasmic life cycle, and therapies
that prevent virus replication can ultimately eradicate the virus
from the host, reducing both the risk of development of liver dis-
ease and the risk of cancer. The former standard of care for
chronic hepatitis C was dual therapy with pegylated alpha inter-
feron and ribavirin, but this was lengthy, poorly tolerated, and
effective in only 50% of persons infected with the most common
HCV genotypes. Over the past decade, intensive research efforts
directed at understanding the HCV life cycle have resulted in the
development of small-molecule inhibitors targeting specific viral
proteins, including the nonstructural 3 (NS3) protease and the
NS5B RNA-dependent RNA polymerase (1). Some of these di-
rect-acting antiviral (DAA) drugs have already been approved for
use in therapy, and several other DAAs are in clinical develop-
ment.
The NS3 protein has emerged as a key target for antiviral drug
development. The genome of HCV encodes a single polyprotein
that is co- and posttranslationally cleaved into 10 individual pro-
teins by cellular and viral proteases. The HCV NS3 protein, to-
gether with its cofactor, NS4A, is a serine protease that is required
to cleave the polyprotein at four sites in order to generate viral
proteins essential for replication of the RNA genome. In addition,
NS3 cleaves the adaptor proteins MAVS (2) and TRIF (3) to block
activation of interferon gene expression through the retinoic acid-
inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3) path-
ways. Thus, the NS3 protease is a particularly attractive target for
antiviral intervention since its inhibition not only interferes with
polyprotein processing but also restores antiviral signaling (4, 5).
The first direct-acting antiviral drugs to be approved for the ther-
apy of chronic hepatitis C, boceprevir (6) and telaprevir (7), are
both peptidomimetic linear ketoamides that target the active site
of the protease domain of NS3. Further development of protease
inhibitors (PIs) with macrocycles at either P1-P3 or P2-P4 re-
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sulted in improved antiviral potency. Recently, simeprevir (8) be-
came the first macrocyclic PI to be approved for the treatment of
chronic hepatitis C in the United States (9). Several other PIs are in
clinical development, including more potent, pan-genotypic PIs,
such as grazoprevir (10).
Although the protease activity of NS3 has been the focus of
drug development efforts, NS3 is a bifunctional enzyme with sep-
arate protease and helicase domains connected by a flexible linker.
The helicase domain has NTPase and 3=-5= RNA unwinding ac-
tivity (11). The ATP-dependent RNA unwinding activity of the
NS3 helicase is essential for HCV RNA synthesis (12), and genetic
and biochemical studies have implicated the NS3 helicase domain
in viral assembly, independently of its role in RNA synthesis (13).
The two domains can be separated and their enzymatic activi-
ties can be studied in vitro, but their attachment in the full-length
NS3 has been shown to strongly influence their individual prop-
erties. For example, the isolated helicase domain preferentially
unwinds DNA substrates, but the presence of the protease domain
in full-length NS3 can alter substrate selectivity and enhance RNA
binding and unwinding (14). Conversely, the helicase domain has
been shown to stimulate protease activity in the context of full-
length protein (15), and polynucleotides, especially polyuracil,
have been shown to stimulate the protease activity of the full-
length NS3 but not the activity of the isolated protease (16). A
recent mutational analysis has shown that the linker region con-
necting the two domains is not required for protease or helicase
activity but is critical for replication and infectivity (17). These
data support a role for the linker either in modulating the confor-
mation of full-length NS3 or in mediating interactions between
NS3 and other viral or host proteins during the HCV life cycle.
Recently, a novel class of allosteric protease/helicase inhibitors
was identified using fragment-based screening and structure-
guided design (18). These inhibitors bind at the interface between
the protease and helicase domains of NS3, a region proposed to
modulate the activities of the two enzyme domains in vivo (19).
To characterize the mechanism of action of allosteric NS3 in-
hibitors, a representative compound from this class, AT23708,
was compared to the active-site PI telaprevir in multiple assays of
antiviral activity that specifically examined different steps in the
viral life cycle, including polyprotein synthesis, RNA synthesis,
and the intracellular assembly and release of infectious genotype
1a virus H77S.3. These assays not only allowed characterization of
the allosteric NS3 inhibitor but also revealed unexpected antiviral
activities of the PI telaprevir on NS3-dependent stages of the viral
life cycle, in addition to polyprotein processing.
Both classes of inhibitor were able to inhibit a late stage in virus
assembly or maturation within 12 h following addition of drug to
infected cells. Additionally, RNA synthesis was almost completely
blocked by telaprevir and partially blocked by AT23708 within 12
h, a time point when there is little detectable reduction in intra-
cellular NS5B levels. These data show that protease inhibitors tar-
geting the multifunctional NS3 protein have an early effect on
RNA synthesis, in addition to polyprotein processing.
MATERIALS AND METHODS
Cell culture and inhibitors. The Huh7 subclone 2-3c (20) is a cured
replicon cell line that is highly permissive for HCV replication and shows
very weak RIG-I signaling following challenge with Sendai virus (21). 2-3c
cells were grown in Dulbecco’s modified Eagle’s medium (Gibco-BRL)
supplemented with 10% fetal calf serum, 100 U penicillin, 100 U strepto-
mycin, 1 mM L-glutamine, 1 nonessential amino acids, 1 M vitamin E,
1 mM sodium pyruvate, and 10 mM HEPES buffer, pH 7.4. For virus
production assays, the concentration of HEPES buffer, pH 7.4, was in-
creased to 50 mM. AT23708, an allosteric NS3 inhibitor (18), and the
active-site PI telaprevir (7) were synthesized at Astex Pharmaceuticals
(Cambridge, United Kingdom). The nonnucleoside polymerase inhibitor
HCV796 (22) was a gift from Anita Howe (Merck Research Laboratories,
Kenilworth, NJ). Stock solutions of telaprevir, AT23708, and HCV796
were prepared in dimethyl sulfoxide (DMSO).
Virus infections and antiviral assays. H77S.3 is a cell culture-adapted
infectious molecular clone of a genotype 1a HCV isolate (23, 24). H77S.3/
GLuc2A is a modified H77S.3 isolate that expresses Gaussia luciferase
(GLuc) as a fusion with its polyprotein. In this genome, the GLuc se-
quence, followed by that of a foot-and-mouth disease virus 2A autopro-
tease, is inserted in frame between the p7 and NS2 sequences of H77S.3.
The cleavage events required for production of mature secreted GLuc are
independent of HCV protease activity. Plasmids encoding the H77S.3 or
H77S.3/GLuc2A genome were linearized by XbaI digestion and tran-
scribed in vitro using a T7 MEGAscript kit (Ambion). RNA products were
DNase treated and purified using an RNeasy minikit (Qiagen) and elec-
troporated into Huh7 cells as described previously (25). Electroporated
cells were cultured for 7 days to allow HCV replication to reach a steady
state before seeding to different plate formats for specific assays of the
virus life cycle. GLuc assays of HCV genome replication and measurement
of infectious HCV production by a focus-forming-unit (FFU) assay have
been described previously (26). To measure the effects of protease inhib-
itors on cell proliferation and viability, a WST-1 assay was used according
to the manufacturer’s protocol (Roche).
Western blot analyses of viral protein abundance. Cells were washed
twice in 1 phosphate-buffered saline (PBS), directly lysed in 1 Laem-
mli sample buffer containing 5% -mercaptoethanol, and passed through
a QIAshredder apparatus (Qiagen) to reduce sample viscosity. Samples
corresponding to 1/10 of a 12-well plate were resolved by SDS-PAGE on a
4 to 15% Tris-glycine gradient gel (Bio-Rad), and total protein was trans-
ferred to a low-fluorescence polyvinylidene difluoride membrane using a
Transblot Turbo transfer system (Bio-Rad) according to the manufactur-
er’s instructions. Blots were probed with primary antibodies against HCV
NS5B (rabbit polyclonal antibody; catalog number ab65410; Abcam) and
-actin (mouse monoclonal antibody; catalog number AC-15; Sigma-
Aldrich). Secondary antibodies were IRDye 800CW goat anti-mouse IgG
and IRDye 680 goat anti-rabbit IgG. Blots were visualized by two-color
detection using an Odyssey infrared imaging system, and bands were
quantified using Odyssey (v3.0) software (LI-COR, Inc.). For each dose of
inhibitor, the abundance of NS5B was normalized to the abundance of
-actin, used as a loading control in the same lane.
Statistical analyses. To determine the 50% effective concentrations
(EC50s) and 90% effective concentrations (EC90s) of telaprevir and
AT23708 in the different assays (GLuc, immunoblot quantitation of re-
sidual NS5B abundance, FFU, and RNA synthesis assays), data were fit to
a four-parameter dose-response curve with variable slope using Prism
(v6.0) software for Windows (GraphPad Software, Inc.). Values reported
are the estimated concentration  95% confidence interval. Maximum
achievable inhibitory activities (maximum-effect [Emax] values) at differ-
ent time points were compared by the Mann-Whitney test using Prism
(v6.0) software.
Measurement of RNA synthesis inhibition. To determine the impact
of NS3 inhibitors on viral RNA synthesis, nascent RNA was labeled by
incubating HCV-infected cells with 5-ethynyl uridine (EU) from 2 to 12 h
after addition of inhibitor. Total RNA was purified from cells using the
RNeasy minikit (Qiagen). EU-labeled RNA was conjugated to biotin and
isolated from the total RNA using a Click-iT nascent RNA capture kit
(Invitrogen). Newly synthesized, EU-labeled HCV RNA and total cell-
associated HCV RNA were quantified using HCV-specific primers and a
2-step quantitative reverse transcription-PCR (qRT-PCR) assay described
previously (23).
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Rate-zonal gradient analyses. Cells were transfected with H77S.3 as
described above and treated for 12 h with either 0.1% DMSO or NS3
inhibitors at concentrations that represent 5 EC90s of those drugs, as
measured by the GLuc assay. After drug treatment, cells were harvested by
trypsinization, washed twice in PBS, and resuspended in 400 l PBS.
Lysates were prepared by multiple freeze-thaw cycles as described previ-
ously (26) and subjected to rate-zonal centrifugation. Clarified lysate (350
l) was loaded onto a 10 to 50% sucrose gradient prepared in TNE (10
mM Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA) and centrifuged for 1 h at
40,000 rpm in an SW55 Ti rotor at 4°C. For each gradient, 20 fractions
were collected from the top of the gradients and analyzed for HCV RNA
by qRT-PCR (23) and for infectivity by FFU assay.
RESULTS
Kinetics of antiviral suppression by different classes of inhibi-
tors that target NS3. As a first step to characterize how inhibitors
that bind at different sites on the NS3 protein impact different
aspects of the HCV life cycle, the kinetics of antiviral activity were
monitored by measuring the Gaussia luciferase (GLuc) activity
secreted from cells infected with genotype 1a cell culture-infec-
tious H77S.3/GLuc2A at different time points following treatment
with either telaprevir (a linear ketoamide that binds the active site
of the NS3 protease domain) or AT23708 (an allosteric protease-
helicase inhibitor [APHI] that binds NS3 at the interface of the
protease and helicase domains). H77S.3/GLuc2A is a modified
version of H77S.3 in which the GLuc-coding sequence has been
inserted between p7 and NS2, followed by the foot-and-mouth
disease virus 2A protein-coding sequence. When H77S.3/GLuc2A
RNA is transfected into Huh7 cells, the RNA can replicate and the
GLuc translated from the replicating genomes is secreted into the
medium. Secreted GLuc is a measure of polyprotein synthesis, but
this correlates well with intracellular RNA levels. Thus, HCV RNA
abundance and polyprotein synthesis can be monitored by mea-
suring GLuc activity in medium collected at 12- or 24-h intervals
following transfection.
In this assay, telaprevir and AT23708 displayed different kinet-
ics of antiviral suppression (Fig. 1A and Table 1). This difference
in kinetics can be seen most easily by comparing the maximum
achievable inhibition (Emax) values for both drugs in the GLuc
assay at different time points (Table 2). Emax values were signifi-
cantly higher for telaprevir than AT23708 at both 24 h (81% ver-
sus 38%; P  0.0022) and 48 h (99% versus 90%; P  0.0022).
WST-1 assays were performed in parallel to determine the im-
pact of telaprevir and AT23708 on cell viability and proliferation
(Fig. 1C). No change in cellular proliferation was observed at 12 or
24 h for either inhibitor. At 48 and 72 h, a modest 20 to 30%
reduction in cell viability/proliferation was observed only at the
highest concentrations tested (25 or 50 M) for both inhibitors.
The 50% cytotoxic concentrations (CC50s) for both inhibitors
were greater than 50 M, the highest concentration tested.
Reduction of intracellular nonstructural protein levels. Ac-
tive-site protease inhibitors such as telaprevir inhibit the NS3-
dependent cleavage events that generate the mature NS proteins
required for RNA genome replication. AT23708 also inhibits NS3-
dependent proteolytic processing in vitro (18). Western blot anal-
yses were used to compare the rates at which each inhibitor re-
duces intracellular nonstructural protein levels.
Huh7 cells were electroporated with H77S.3 RNA genomes
and cultured for 1 week to allow virus replication to stabilize.
Infected cells were mock treated (0.1% DMSO) or treated with
telaprevir or AT23708 at concentrations ranging from 25 nM to 50
M for 72, 48, 24, or 12 h prior to harvest, at which time cell lysates
were prepared and subjected to SDS-PAGE and Western blotting.
Membranes were probed for HCV NS5B or core protein with
actin or -tubulin as a loading control.
The rates of reduction of NS5B protein abundance by both
telaprevir and AT23708 were low (Fig. 1B and Table 3). In agree-
ment with the findings of the GLuc assays (Fig. 1A), the rate of
reduction of NS5B abundance was slightly higher following addi-
tion of telaprevir than following addition of AT23708. As was the
case for the GLuc assay, the difference in kinetics can be seen most
easily by comparing the Emax values for both drugs in the NS5B
Western blot assay at different time points (Table 2). Emax values
were significantly higher for telaprevir than AT23708 at both 24 h
(85% versus 48%; P  0.0022) and 48 h (100% versus 78%; P 
0.0159). Importantly, at 12 h after addition of either drug there
was little detectable reduction in intracellular NS5B abundance.
This observation allowed us to perform further analyses focusing
on RNA synthesis and infectious virus production at early time
points after addition of drug when protease inhibition is not yet
resulting in significant decreases in NS5B abundance.
Inhibition of RNA synthesis by DAAs targeting NS3. To di-
rectly investigate inhibition of RNA synthesis, nascent RNA was
labeled by incubating HCV-infected cells with 5-ethynyl uridine
(EU) from 2 to 12 h after addition of inhibitor. Total RNA was
extracted from the cells, and following isolation of EU-labeled
RNA, newly synthesized HCV RNA genomes were quantified by
qRT-PCR. Total residual HCV RNA abundance was also quanti-
fied by qRT-PCR at 12 h after inhibitor addition (Fig. 2A). The
rate of reduction of newly synthesized HCV RNA (Fig. 2B) was
higher than that of total residual HCV RNA for both inhibitors,
suggesting that they primarily act to reduce new RNA synthesis
and do not accelerate degradation of existing viral RNA genomes.
Telaprevir was able to almost completely inhibit HCV RNA syn-
thesis (Emax, 92%) within 12 h of drug addition at high but clini-
cally relevant concentrations (Fig. 2B, left). These data suggest
that telaprevir can directly interfere with NS3 activity during RNA
synthesis independently of its inhibitory activity on proteolytic
processing, since at 12 h after addition of drug there was little
reduction of intracellular NS5B (Fig. 1B).
In contrast to telaprevir, AT23708 showed only partial inhibi-
tion of HCV RNA synthesis at 12 h after addition (Emax, 53%; Fig.
2B, right). The difference between telaprevir and AT23708 in the
early kinetics of RNA synthesis inhibition correlates with the dif-
ference in kinetics observed in the GLuc assay and is consistent
with a model in which binding of AT23708 to NS3 is conforma-
tion dependent (see Discussion).
Inhibition of virus production by DAAs targeting NS3. To
compare the inhibition of virus production by the active-site PI
and allosteric NS3 inhibitor, an FFU assay was used to measure the
amount of infectious virus produced from H77S.3-infected cells at
different 12- to 24-h intervals following addition of the inhibitors.
Inhibition of virus production was rapid and occurred sooner
than inhibition of RNA genome replication for both telaprevir
and AT23708 (Fig. 3A and Table 4). The difference between the
timing of inhibition of RNA synthesis and the timing of virus
production was particularly striking for AT23708. Complete inhi-
bition of virus production was observed with AT23708 by 12 h
after addition, a time point when there was incomplete inhibition
of RNA synthesis (Fig. 2) and no reduction in intracellular non-
structural protein levels (Fig. 1B). Telaprevir was also able to block
McGivern et al.
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virus production at 12 h after addition (Fig. 3), but at this time
point, telaprevir could also inhibit RNA synthesis (Fig. 2B). Sev-
eral further lines of evidence suggest that telaprevir has an addi-
tional effect on virus production. First, the EC50 at 12 h in the virus
production (FFU) assay was 777 nM (Table 4), whereas it was
2,400 nM in the RNA synthesis assay (Fig. 2). Furthermore, at very
early time points following addition of inhibitor at 5 times the
EC90, both telaprevir and AT23708 were able to block virus pro-
FIG 1 (A) Kinetic analysis of the suppression of H77S.3/GLuc2A virus replication by the active-site protease inhibitor telaprevir or the allosteric NS3 inhibitor
AT23708. Huh7 cells were electroporated with H77S.3/GLuc2A RNA genomes and passaged for 1 week before they were challenged with an inhibitor over a range
of concentrations. At 12, 24, 48, and 72 h following addition of inhibitor, the cell culture media were harvested and replaced with fresh medium containing
inhibitor. The percent inhibition of GLuc activity in cell culture medium is plotted on the y axis, where 0% is the GLuc activity in cells treated with medium
containing DMSO vehicle only (no inhibitor) and 100% inhibition is a reduction of GLuc activity to background levels (determined by measurement of GLuc
activity in medium from cells transfected with a replication-incompetent RNA genome, H77S-AAG/GLuc2A). The data shown represent the mean  SEM from
3 replicates of an experiment representative of multiple experiments. Data were fit to dose-response curves as described in Materials and Methods. EC50 and EC90
values for telaprevir and AT23708 in the GLuc assay are shown in Table 1. (B) Reduction of intracellular NS5B abundance following addition of telaprevir or
AT23708 to Huh7 cells infected with H77S.3. NS5B and -actin were detected in cell lysates by Western blotting. NS5B levels were normalized using -actin as
a loading control. Normalized NS5B abundance was expressed as percent inhibition, where 0% is the NS5B abundance in cells treated with the DMSO vehicle
only and 100% inhibition is a reduction of NS5B levels to background levels (determined using lysates from uninfected cells). The data shown represent the
mean  SEM percent inhibition from 3 independent experiments. EC50 and EC90 values for telaprevir and AT23708 in the Western blot analyses are shown in
Table 3. (C) Effect of telaprevir and AT23708 on cell proliferation and viability measured by a WST-1 cell proliferation assay. The data shown are normalized to
the values obtained from cells grown in medium containing 0.1% DMSO vehicle and represent the mean  SEM from 3 independent experiments.
TABLE 1 EC50s and EC90s of NS3 inhibitors against H77S.3/GLuc2A virus determined by GLuc assay
Inhibitor
EC50 (nM) EC90 (nM)
12 h 24 h 48 h 72 h 12 h 24 h 48 h 72 h
Telaprevir 50,000a 2,180 (1,100–4,317)b 749 (614–914) 584 (406–840) 50,000 50,000 1,366 (940–1,985) 1,564 (677–3,612)
AT23708 50,000 50,000 889 (525–1,503) 274 (131–573) 50,000 50,000 6,519 (907–46,860) 1,023 (189.5–5,521)
a The highest concentration tested.
b The values in parentheses are 95% confidence intervals.
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duction faster than the RNA-dependent RNA polymerase inhibi-
tor HCV796 (Fig. 3B). These data suggest that telaprevir is also
able to inhibit virus production, in addition to blocking RNA
synthesis and polyprotein processing. When the results of the dif-
ferent assays were compared, Emax values (Table 2) were signifi-
cantly greater when they were measured in the virus production
assay than when they were measured in the GLuc or NS5B West-
ern blot assays for telaprevir at 12 and 24 h and for AT23708 at 12,
24, and 48 h (P  0.01 in every case).
A potential caveat in this experiment is that infectious virus
production is measured in medium containing inhibitor. In the
virus production assay, H77S.3-infected cells were treated with
different concentrations of protease inhibitor and medium was
harvested at various times after treatment. Virus released into the
medium was used to inoculate naive cells for 4 h before the inoc-
ulum was washed off and the medium was replaced with fresh
medium. After a further 3 days of culture, inoculated cells were
stained for core protein to quantify infectious foci. Although the
inoculum was washed out in this experimental design, it is possi-
ble that residual amounts of inhibitor were being carried over
during the 4-h inoculation period and blocking cleavage of poly-
protein translated from newly uncoated viral RNA following en-
try. To determine the contribution of drug carryover in this assay,
the virus inoculum produced from cells grown in the absence of
drug was spiked with an equal volume of conditioned cell culture
medium from mock-infected cells treated for 12 h with a range of
inhibitor concentrations, this mixture was used to inoculate naive
cells for 4 h, and virus infectivity was assessed by FFU assay (Fig.
3A, carryover). Inhibition of virus infectivity by drug carryover
was observed only at concentrations of 12.5 M or higher for both
telaprevir and AT23708, concentrations approximately 20- or
100-fold higher, respectively, than the concentrations required to
block virus production. These data confirm that the rapid de-
crease in the number of FFU following protease inhibitor treat-
ment is a genuine effect on virus production and not simply due to
the inhibition of virus infectivity caused by drug carryover.
During the assembly of HCV, NS3 is recruited to lipid droplets
along with the NS5A protein (27). Our previous studies suggested
that production of HCV particles is a dynamic process that can be
rapidly inhibited by DAAs that target viral proteins involved in
assembly, such as NS5A (26). Whether inhibitors that target NS3
impact viral assembly or maturation is not known, but genetic and
biochemical studies have suggested a role for the helicase domain
of NS3 in virus assembly (13). Thus, it is possible that inhibitors
targeting NS3 could have a direct effect on intracellular assembly.
To assess this, infected cells were treated with a high concentration
(5 M; 5 EC90 in the GLuc assay at 72 h) of telaprevir or
AT23708 for 12 h. The cells were then lysed by repeated freeze-
thaw cycles in the absence of detergent, and intracellular viral
particles were separated by rate-zonal ultracentrifugation through
a sucrose gradient. Fractions collected from the top of the gradient
were analyzed by qRT-PCR to determine the HCV genomic RNA
content and the FFU assay to determine the infectious virus con-
tent (Fig. 4). Although the total amount of viral RNA in lysates
from inhibitor-treated cells was reduced by 40 to 45% compared
with that in lysates from cells treated only with DMSO, the pres-
ence of discrete peaks of HCV RNA in fractions 7 and 10 of the
gradients suggested the continued assembly of RNA-containing
particles in the presence of inhibitor. Infectious virus was clearly
present and sedimenting with the second RNA peak in fractions 9
and 10 of the gradient loaded with lysate from mock-treated cells.
Importantly, however, there was a sharp reduction in the amount
of infectious virus in the fractions from cells treated with AT23708
or telaprevir.
Collectively, the data suggest that NS3 inhibitors block a late
step in the intracellular assembly and/or maturation of virus, re-
sulting in the early and nearly complete inhibition of production
of infectious virus.




12 h 24 h 48 h 72 h
Telaprevir
GLuc assay 16.67  3.08 80.83  2.09 99.01  0.28 99.94  0.02
NS5B reduction by Western blotting 34.29  6.18 84.99  7.61 100  0.01 100  0.27
Virus production by FFU assay 100  0.01 100  0.01 100  0.01 100  0.01
AT23708
GLuc assay 19.16  3.10 38.06  3.39 89.99  2.87 99.54  0.39
NS5B reduction by Western blotting 27.92  0.97 48.39  2.24 77.64  1.45 100  0.44
Virus production by FFU assay 99.89  0.07 100  0.01 99.71  0.26 100  0.01
a Data represent the mean  standard error of the mean Emax values from 3 experiments.
TABLE 3 EC50s and EC90s of NS3 inhibitors against H77S.3 virus assessed by determination of NS5B reduction by Western blotting
Inhibitor
EC50 (nM) EC90 (nM)
12 h 24 h 48 h 72 h 12 h 24 h 48 h 72 h
Telaprevir 25,760 1,076 (241–4,803)a 608 (97–3,823) 1,099 (908–1,329) 50,000b 28,729 (327–50,000) 1,878 (112–50,000) 2,366 (1,455–3,846)
AT23708 50,000 351 (120–1,027) 399 (192–830) 364 (161–822) 50,000 50,000 50,000 1,750 (357–8,588)
a The values in parentheses are 95% confidence intervals.
b The highest concentration tested.
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DISCUSSION
In this study, the active-site PI telaprevir was compared with a
novel allosteric NS3 inhibitor in cell-based assays that focus on
different aspects of the HCV life cycle. Many viral proteins are
multifunctional, and DAAs may hit one or multiple functions of
their target protein. The use of multiple assays to probe the HCV
life cycle in detail can help provide an understanding of how DAAs
interfere with the life cycle and illuminate the role of specific pro-
teins in virus replication.
Protease inhibitors can directly interfere with RNA synthe-
sis. In addition to blocking the NS3-dependent cleavage of the
HCV polyprotein, the active-site PI telaprevir was found to inhibit
new RNA synthesis and virus production prior to egress at a late
stage during assembly or particle maturation. Since the HCV
RNA-dependent RNA polymerase NS5B is generated by NS3-de-
pendent cleavage of the polyprotein, inhibition of RNA synthesis
by a PI such as telaprevir could be a consequence of depletion of
intracellular NS5B. However, inhibition of RNA synthesis by tel-
aprevir occurred at 2 to 12 h after addition of the drug, a time
point when there is little reduction in NS5B abundance, suggest-
ing that telaprevir can directly inhibit RNA synthesis. This activity
of an active-site PI is unexpected but is consistent with a role for
the protease domain during RNA synthesis. Previous biochemical
studies have shown that the protease domain of NS3 is required
for efficient unwinding of double-stranded RNA (dsRNA) by the
helicase (28), and recently, Aydin et al. (19) proposed a model in
which the protease domain of NS3 binds to dsRNA as a clamp
while the helicase unwinds the double-stranded template to allow
access by NS5B to the negative strand for RNA synthesis. It is
tempting to speculate that binding of telaprevir to the protease
domain may inhibit RNA synthesis by reducing helicase activity,
but a previous study has reported that telaprevir does not inhibit
the helicase activity of full-length NS3 in vitro (29). In vivo, how-
ever, NS3 functions as part of a multiprotein replicase complex
where binding of telaprevir may result in disruption of protein-
protein and protein-RNA interactions to block a function of NS3
in RNA synthesis. An alternative explanation is that the majority
of new RNA synthesis is performed by newly synthesized NS5B.
Further experiments will be required to test these hypotheses.
The APHI AT23708, already known to act as an inhibitor of poly-
protein processing, was also able to inhibit RNA synthesis at early
time points following addition of drug, but unlike the inhibition
caused by telaprevir, the inhibition was only partial. This difference
may be explained by the conformation-dependent binding of the
APHI to NS3, in which the APHI targets a site in the interdomain
interface that is present in the compact crystallographic conforma-
tion of NS3 but not in the extended conformation, which biochemi-
cal studies suggest represents the active conformation during RNA
synthesis (30). Partial inhibition of RNA synthesis by AT23708 is
consistent with NS3 adopting the extended conformation at least
some of the time during RNA synthesis.
FIG 3 Rapid inhibition of virus production by telaprevir and AT23708. (A) Reductions in infectious virus released into supernatants between 0 and 12, 12 and
24, 24 and 48, and 48 and 72 h after infected cell cultures were challenged with a range of concentrations of telaprevir or AT23708. Infectious virus release was
quantified by the FFU assay. The reduction in virus infectivity caused by residual inhibitor present in the inoculum was measured and is plotted as the carryover.
Results are shown as percent inhibition, where 0% is the number of FFU per milliliter released from infected cells grown in the absence of inhibitor (DMSO
vehicle only) and 100% inhibition is a reduction of the level of virus production to below the limit of detection (10 FFU/ml). The data shown represent the
mean  SEM from 2 to 3 independent experiments and were fit to a dose-response curve, as described in the legend to Fig. 1. EC50 and EC90 values for telaprevir
and AT23708 in the FFU assay are shown in Table 4. (B) Very early inhibition of virus production by telaprevir and AT23708 compared to that by the
nonnucleoside RNA-dependent RNA polymerase inhibitor HCV796. Inhibitors were added at 2-h intervals to H77S.3-infected cells at concentrations equivalent
to 5 EC90 in the 72 h GLuc assay. At 6 h, medium was removed from all cultures and replaced with fresh medium containing the inhibitors. Supernatants were
harvested 3 h later, and infectious virus was quantified by the FFU assay.
FIG 2 (A) Reduction of total residual HCV RNA in H77S.3-infected Huh7
cells by telaprevir or AT23708 at 12 h. (B) Inhibition of new HCV RNA syn-
thesis in H77S.3-infected Huh7 cells by telaprevir or AT23708 between 2 and
12 h. The shaded area in the left-hand panel represents a previously reported
range of telaprevir concentrations (minimum concentration, 3.0 M; maxi-
mum concentration, 5.2 M) in the plasma of persons treated with 750 mg
telaprevir every 8 h (4). The data shown represent the mean  SEM percent
inhibition from 3 experiments and were fit to a dose-response curve, as de-
scribed in the legend to Fig. 1.
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Protease inhibitors can interfere with virus assembly/matu-
ration. Both telaprevir and AT23708 were able to rapidly inhibit
virus production from infected cells. Inhibition occurred at early
time points (12 h after drug addition), when there was little reduc-
tion of residual HCV RNA in the cells and no reduction in intra-
cellular levels of nonstructural proteins. Analyses at very early
time points showed the onset of inhibition by 3 h following addi-
tion of drug and 90% inhibition by 9 h. The different kinetics of
inhibition of virus assembly compared to the kinetics of inhibition
of RNA synthesis and reduction of NS5B abundance suggest that
(i) assembly is a highly dynamic process and particles are exported
rapidly from the cell and (ii) the pool of NS3 involved in virus
assembly is distinct from the pool of NS3 involved in RNA syn-
thesis and polyprotein processing.
Our data show that inhibitors targeting NS3 at either the active
site or an allosteric site in the interdomain interface can block
virus production at a late step during assembly/maturation of the
virus particles. While this specific effect of NS3/4A inhibitors has
not been demonstrated previously, it is not surprising, as NS3 is
recruited to lipid droplets together with NS5A and appears to
function directly in viral assembly (13, 27). Some variants associ-
ated with resistance to NS3/4A inhibitors also impair viral fitness
by negatively impacting steps involved in the release of infectious
virus (23). Our data are in agreement with those from a previous
study (31) that focused on daclatasvir but also included data ob-
tained using mathematical modeling analyses of rates of viral RNA
decline in patient serum following telaprevir treatment suggesting
that telaprevir can block virus production. Those modeling anal-
yses predicted that telaprevir can inhibit virus assembly/secretion
more effectively than polymerase inhibitors but that this effect is
weaker than that for NS5A inhibitors, such as daclatasvir.
How might inhibitors targeting NS3 block assembly? It is pos-
sible that binding of telaprevir to the active site or AT23708 to the
allosteric site inhibits virus release by interfering with an activity of
the protease in viral assembly/release. NS3 is a multifunctional
protein, and the activity of its helicase is regulated through its
protease-helicase domain interface (19). The binding of a small
molecule to the protease domain or at the interdomain interface
might thus alter helicase activity during these final steps in the
viral life cycle. The interaction of inhibitors with NS3 may prevent
an interaction of the helicase domain with core protein, which
genetic (32) and biochemical (33) studies suggest is required for
particle assembly. The effect of telaprevir and AT23708 on viral
release could also occur indirectly via NS5A, as NS5A hyperphos-
phorylation is dependent upon NS3 protease activity (34), and its
absence might affect NS5A functions involved in viral assembly
and release. Further experiments will be required to distinguish
between these possibilities.
The protease activity of NS3/4A is responsible for blunting
RIG-I-dependent host innate immune responses through cleav-
age of the signaling adaptor molecule MAVS (2). Two previous
studies have demonstrated that small-molecule inhibition of NS3
can restore host cell innate immune signaling by preventing the
cleavage of MAVS (4, 5). Kinetic analyses demonstrated that res-
toration of signaling was faster with a protease inhibitor (2 to 4
days, depending upon the concentration) than with a polymerase
inhibitor (7 days) (4). Importantly, the rapid effects (12 h) on
virus production and RNA synthesis observed in the present study
precede (and are thus likely to be independent of) the restoration
of innate immune signaling observed in previous studies. PI-me-
diated restoration of MAVS signaling may be slower than direct PI
effects on the viral life cycle because it requires several events,
including synthesis of a new MAVS protein, trafficking of MAVS
and accumulation at the mitochondrion-associated membranes
(35), interaction with RIG-I molecules engaged with the HCV
TABLE 4 EC50s and EC90s of NS3 inhibitors against H77S.3 virus determined by FFU assay
Inhibitor
EC50 (nM) EC90 (nM)
12 h 24 h 48 h 72 h 12 h 24 h 48 h 72 h
Telaprevir 777 (686–880)a 677 (626–733) 765 (695–843) 738 (566–962) 2,778 (2,085–3,701) 1,389 (1,180–1,635) 1,255 (1,080–1,458) 2,493 (1,333–4,664)
AT23708 218 (200–237) 91 (81–101) 108 (97–121) 123 (98–105) 491 (413–583) 428 (328–558) 364 (285–466) 294 (253–342)
a The values in parentheses are 95% confidence intervals.
FIG 4 Rate-zonal centrifugation of cell lysates derived from H77S.3-trans-
fected cells that were either mock treated (A) or treated with 5 M telaprevir
(B) or 5 M AT23708 (C) for 12 h. Fractions collected from the top of the
gradients were tested for HCV RNA by qRT-PCR and for infectivity by the FFU
assay.
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pathogen-associated molecular pattern, and subsequent down-
stream signaling to promote the expression of antiviral genes (36).
The HCV genome encodes only 10 mature proteins, and many
of these proteins have to be multifunctional to perform all of the
activities required to complete the viral life cycle. For example,
NS5A is involved in the assembly of new replicase complexes but is
also required for virion assembly, and inhibitors targeting NS5A
can block both of these processes (26, 31, 37). NS3 has been
termed the Swiss Army knife of HCV because of its multiple roles
in the viral life cycle (38). The current study has provided novel
insight into how NS3 inhibitors impact specific steps in the viral
life cycle and demonstrates that their mechanism of action is more
complex than simply blocking NS3-dependent polyprotein cleav-
age to prevent replicase complex formation.
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